SAN

73.32

+0.23%↑

SRT3

211

-2.34%↓

ORNBV.FI

-1.42%↓

PHMA

96.4

+0.84%↑

DRW3

85.3

-2.51%↓

SAN

73.32

+0.23%↑

SRT3

211

-2.34%↓

ORNBV.FI

-1.42%↓

PHMA

96.4

+0.84%↑

DRW3

85.3

-2.51%↓

SAN

73.32

+0.23%↑

SRT3

211

-2.34%↓

ORNBV.FI

-1.42%↓

PHMA

96.4

+0.84%↑

DRW3

85.3

-2.51%↓

SAN

73.32

+0.23%↑

SRT3

211

-2.34%↓

ORNBV.FI

-1.42%↓

PHMA

96.4

+0.84%↑

DRW3

85.3

-2.51%↓

SAN

73.32

+0.23%↑

SRT3

211

-2.34%↓

ORNBV.FI

-1.42%↓

PHMA

96.4

+0.84%↑

DRW3

85.3

-2.51%↓

Home・Aandelen Lijst・Gerresheimer AG

Gerresheimer AG

Gesloten

SectorGezondheidszorg

28.2 -0.14

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

27.28

Max

28.81

Belangrijke statistieken
By Trading Economics
Inkomsten	-30M -13M
Verkoop	-40M 561M
K/W Sectorgemiddelde	41.265 49.8
Dividendrendement	0.15
Winstmarge	-2.265
Werknemers	13,535
EBITDA	-45M 74M

Aanbevelingen
By TipRanks
Aanbevelingen	Sell
12 Maanden Prognose	-33.86% downside

Dividenden
By Dow Jones
Dividendrendement Sectorgemiddelde	0.15% 2.25%
Volgende Winsten	14 jul 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	46M 969M
Vorige openingsprijs	28.34
Vorige sluitingsprijs	28.2

Nieuwssentiment

By Acuity

18%

82%

155 / 346 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

60.1 / 60.95 Steun & Weerstand

Gerresheimer AG Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 mei 2026, 22:50 UTC

Winsten

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12 mei 2026, 22:49 UTC

Winsten

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12 mei 2026, 22:32 UTC

Winsten

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12 mei 2026, 23:48 UTC

Marktinformatie

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12 mei 2026, 22:57 UTC

Marktinformatie

Winsten

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12 mei 2026, 22:26 UTC

Winsten

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12 mei 2026, 22:25 UTC

Winsten

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12 mei 2026, 22:25 UTC

Winsten

Aristocrat Leisure Interim Dividend A$0.50/Security

12 mei 2026, 22:24 UTC

Winsten

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12 mei 2026, 22:23 UTC

Winsten

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12 mei 2026, 22:23 UTC

Winsten

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12 mei 2026, 22:19 UTC

Winsten

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12 mei 2026, 22:14 UTC

Winsten

CBA: Business Lending Continued to Grow Above System>CBA.AU

12 mei 2026, 22:14 UTC

Winsten

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12 mei 2026, 22:13 UTC

Winsten

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12 mei 2026, 22:12 UTC

Winsten

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12 mei 2026, 22:12 UTC

Winsten

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12 mei 2026, 22:11 UTC

Winsten

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12 mei 2026, 22:11 UTC

Winsten

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12 mei 2026, 22:10 UTC

Winsten

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12 mei 2026, 22:09 UTC

Winsten

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12 mei 2026, 22:09 UTC

Winsten

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12 mei 2026, 22:08 UTC

Winsten

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12 mei 2026, 22:07 UTC

Winsten

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12 mei 2026, 22:06 UTC

Winsten

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12 mei 2026, 22:06 UTC

Winsten

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12 mei 2026, 22:05 UTC

Winsten

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12 mei 2026, 22:04 UTC

Winsten

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12 mei 2026, 22:04 UTC

Winsten

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12 mei 2026, 22:04 UTC

Winsten

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Peer Vergelijking

Prijswijziging

Gerresheimer AG Prognose

Koersdoel

By TipRanks

-33.86% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 18.56 EUR -33.86%

Hoogste 22 EUR

Laagste 12.9 EUR

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Gerresheimer AG - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Sell

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Gerresheimer AG - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

60.1 / 60.95Steun & Weerstand

Bullish events outweigh bearish events.

Bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

155 / 346 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Gerresheimer AG

Gerresheimer AG, together with its subsidiaries, manufactures and sells medicine packaging, drug delivery devices, and solutions in Germany and internationally. It operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The company offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and glass bottles and jars, as well as caps, closures, applicators, and accessories; development, industrialization and contract manufacturing of drug delivery programs; project and quality management; and drug delivery systems, including inhalers, injection/auto injectors, pen injectors, infusion systems, and inhalation assessment, autoinjector, and other services. It also provides diagnostic and medical devices comprising point-of-care tests, laboratory disposables, chemical and technical bottles, diagnostic and polymer vials, dropper bottles, PET bottles, and medical products comprising lancing devices, infusion sets, and disposable systems. In addition, the company offers cosmetic packaging solutions, such as moulded glass flacons and jars; tubular glass ampoules, droppers, samplers and vials; and plastic packaging products, as well as pharmaceutical, laboratory, and regulatory affairs services. It offers its products to pharmacy chains, supermarkets, and wholesalers. The company serves pharma, biotech, medical technology, diagnostics, cosmetics, glass containers, and food and beverage industries. Gerresheimer AG was founded in 1864 and is based in Düsseldorf, Germany.